This is an outdated version published on 06-03-2026. Read the most recent version.

A complete study of Doxazosin characterization

Authors

  • Itamar Luís Gonçalves Laboratório de Síntese Orgânica Medicinal/LaSOM do Programa de Pós-Graduação em Ciências Farmacêuticas/PPGCF da Universidade Federal do Rio Grande do Sul
  • Mariana Maier Gaelzer Programa de Pós-Graduação em Ciências Biológicas: Bioquímica do Instituto de Ciências Básicas da Saúde da Universidade Federal do Rio Grande do Sul
  • Gabriel Oliveira de Azambuja Laboratório de Síntese Orgânica Medicinal/LaSOM do Programa de Pós-Graduação em Ciências Farmacêuticas/PPGCF da Universidade Federal do Rio Grande do Sul
  • Christianne Gazzana Salbego Programa de Pós-Graduação em Ciências Biológicas: Bioquímica do Instituto de Ciências Básicas da Saúde da Universidade Federal do Rio Grande do Sul
  • Vera Lucia Eifler-Lima Laboratório de Síntese Orgânica Medicinal/LaSOM do Programa de Pós-Graduação em Ciências Farmacêuticas/PPGCF da Universidade Federal do Rio Grande do Sul

DOI:

https://doi.org/10.22456/2527-2616.73960

Keywords:

doxazosin, NMR, FT-IR, signals assignment

Abstract

Doxazosin is an important drug used to treat hypertension and prostatic hyperplasia. An enantiomeric (R)/(S) doxazosin
mesylate mixture was complete characterized by NMR and additionally FT-IR spectroscopy techniques. Different NMR
experiments were performed, such as APT, HSQC, and HMBC in order to confirm the NMR signals assignments. All the
hydrogens and most of carbons atoms were assigned. In this context, the results reported here, consists in important
information for identification and quality control of doxazosin mesylate.

Downloads

Download data is not yet available.

References

Wykretowicz, A., Guzik, P., Wysocki, H. Doxazosin

in the current treatment of hypertension. Expert

opinion on pharmacotherapy. 2008;9(4):625-33.

Wilt, T.J., MacDonald, R. Doxazosin in the

treatment of benign prostatic hypertrophy: an update.

Clinical interventions in aging. 2006;1(4):389.

Pfizer. Company History 2017 [cited 2017

20/07/2017]. Available from:

http://www.pfizer.com/about/history/all.

Gaelzer, M.M., Coelho, B.P., de Quadros, A.H.,

Hoppe, J.B., Terra, S.R., Guerra, M.C.B., et al.

Phosphatidylinositol 3-Kinase/AKT pathway inhibition

by doxazosin promotes glioblastoma cells death,

upregulation of p53 and triggers low neurotoxicity.

PloS one. 2016;11(4):e0154612.

Pantziarka, P., Bouche, G., Meheus, L., Sukhatme,

V., Sukhatme, V.P., Vikas, P. The repurposing drugs in

oncology (ReDO) project. ecancermedicalscience.

2014;8.

González-Juanatey, J.R., Iglesias, M.J., Alcaide, C.,

Piñeiro, R., Lago, F. Doxazosin induces apoptosis in

cardiomyocytes cultured in vitro by a mechanism that

is independent of α 1-adrenergic blockade. Circulation.

2003;107(1):127-31.

Nikolic, K., Filipic, S., Smoliński, A., Kaliszan, R.,

Agbaba, D. Partial least square and hierarchical

clustering in ADMET modeling: Prediction of blood–

brain barrier permeation of α-adrenergic and

imidazoline receptor ligands. Journal of Pharmacy &

Pharmaceutical Sciences. 2013;16(4):622-47.

Bakshi, M., Ojha, T., Singh, S. Validated specific

HPLC methods for determination of prazosin, terazosin

and doxazosin in the presence of degradation products

formed under ICH-recommended stress conditions.

Journal of Pharmaceutical and Biomedical Analysis.

2004;34(1):19-26.

Yuan, X-R., Liu, Y-H., Li, R-Y., Chen, X-X.

Experimental and theoretical NMR study of (s)-

doxazosin. Acta Physico-Chimica Sinica.

2008;24(6):1058-62.

Loidreau, Y., Besson, T. Microwave-assisted

thermal decomposition of formamide: a tool for

coupling a pyrimidine ring with an aromatic partner.

Tetrahedron. 2011;67(26):4852-7.

Rouf, A., Aga, M.A., Kumar, B., Taneja, S.C. A

facile approach to chiral 1, 4-benzodioxane toward the

syntheses of doxazosin, prosympal, piperoxan, and

dibozane. Tetrahedron Letters. 2013;54(48):6420-2.

Tsyskovskaia, I., Kandil, M., Beaumier, Y.

Synthesis of a New Doxazosin‐Related Compound.

Synthetic communications. 2007;37(3):447-50.

Zhang, L-Y., Wang, B-L., Zhan, Y-Z., Zhang, Y.,

Zhang, X., Li, Z-M. Synthesis and biological activities

of some fluorine- and piperazine-containing 1,2,4-

triazole thione derivatives. Chinese Chemical Letters.

2016;27(1):163-7.

Koester, L.S., Guterres, S.S., Le Roch, M., Eifler-

Lima, V.L., Zuanazzi, J.A., Bassani, V.L. Ofloxacin/β-

Cyclodextrin Complexation. Drug Development and

Industrial Pharmacy. 2001;27(6):533-40.

Commission BP. British Pharmacopoeia.

London2013.

Pharmacopeia U. United States Pharmacopeia. The

Standard USA: US Pharmacopeia 1995. 2002.

Downloads

Published

28-08-2017 — Updated on 06-03-2026

Versions

How to Cite

Gonçalves, I. L., Maier Gaelzer, M., Oliveira de Azambuja, G., Gazzana Salbego, C., & Eifler-Lima, V. L. (2026). A complete study of Doxazosin characterization. Drug Analytical Research, 1(1), 56–60. https://doi.org/10.22456/2527-2616.73960 (Original work published August 28, 2017)

Issue

Vol. 1 No. 1 (2017)

Section

ORIGINAL ARTICLES

License

Copyright (c) 2017 Drug Analytical Research

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The Copyright holder of manuscripts published is Drug Analytical Research. Authors who publish with this journal are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.


Licensing:

Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License

Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author.

Crossref
Scopus
Google Scholar
Europe PMC